MedTrace Logo

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

NCT04129515 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2026-01-02

No results posted yet for this study

Summary

This research study involves studying a device as a possible treatment for metastatic melanoma in the brain. The purpose of this study is to obtain information on the safety and effectiveness of the study device, NovoTTF-200A, in melanoma participants with brain metastases when it is combined with Pembrolizumab.

The name of the study device involved in this study is:

\-- NovoTTF-200A

The name of the drug used in this study is:

\-- Pembrolizumab

Conditions

Interventions

DEVICE

NovoTTF-200A

•NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle

DRUG

Pembrolizumab

Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle

Sponsors & Collaborators

  • NovoCure Ltd.

    collaborator INDUSTRY

  • Brown University

    lead OTHER

Principal Investigators

  • Eric T Wong, MD · Lifespan Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-30
Primary Completion
2025-12-31
Completion
2026-01-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04129515 on ClinicalTrials.gov